行情

PCRX

PCRX

PACIRA制药
NASDAQ

实时行情|Nasdaq Last Sale

43.82
-0.18
-0.41%
盘后: 43.82 0 0.00% 17:10 01/17 EST
开盘
44.09
昨收
44.00
最高
44.62
最低
43.36
成交量
62.65万
成交额
--
52周最高
49.50
52周最低
34.64
市值
18.29亿
市盈率(TTM)
834.67
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PCRX 新闻

  • ASRT or PCRX: Which Is the Better Value Stock Right Now?
  • Zacks.5天前
  • Pacira Bio sees FY 2019 net revenue as high as $421M
  • Seeking Alpha - Article.01/09 14:18
  • Pacira Biosciences Sees FY19 Sales $421M vs $418.1M Estimate
  • Benzinga.01/09 12:33
  • Pacira BioSciences Reports Full-Year 2019 Preliminary Revenue of $421.0 Million
  • GlobeNewswire.01/09 12:30

更多

所属板块

制药
+0.13%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

PCRX 简况

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
展开

Webull提供Pacira Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。